Grundlæggende statistik
| LEI | 506700O6IRRIQLT3W370 |
| CIK | 1674416 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CRISPR Therapeutics AG
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 5, 2026 |
As filed with the Securities and Exchange Commission on June 5, 2026 As filed with the Securities and Exchange Commission on June 5, 2026 Registration No. |
|
| June 5, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 CRISPR Therapeutics AG Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, CHF 0. |
|
| June 4, 2026 |
Exhibit 10.4 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Common Share: $ Grant Date: Expiration Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Th |
|
| June 4, 2026 |
CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Exhibit 10.1 CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of CRISPR Therapeutics AG (the “Company”) and its Affiliat |
|
| June 4, 2026 |
Exhibit 3.1 Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit |
|
| June 4, 2026 |
Exhibit 10.5 RESTRICTED STOCK AWARD AGREEMENT UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Shares: Grant Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Shares |
|
| June 4, 2026 |
Exhibit 10.2 INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Common Share: $ Grant Date: Expiration Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) h |
|
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 4, 2026 |
Exhibit 10.3 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Common Share: $ Grant Date: Expiration Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therape |
|
| June 4, 2026 |
Exhibit 10.6 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of |
|
| June 4, 2026 |
Exhibit 10.7 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AG 2026 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan as amended and in effect from time to time (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an awa |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 |
|
| May 4, 2026 |
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results ZUG, Switzerland and BOSTON, May 4, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflected continued execution across CRISPR Therapeutics’ platform,” said Samarth Kulkarni, Ph.D., Chairman and Chief E |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 21, 2026 |
2025 ANNUAL REPORT Transformative Gene-Based Medicines For Serious Human DiseasesWe are rapidly translating the revolutionary CRISPR technology into therapies to treat a broad range of serious human diseases. |
|
| April 21, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 2, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 16, 2026 |
Exhibit 4.1 CRISPR THERAPEUTICS AG AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 16, 2026 1.7308% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 14 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation and Amoun |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 11, 2026 |
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering Exhibit 99.2 CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering ZUG, Switzerland and BOSTON, March 11, 2026 – CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified instit |
|
| March 11, 2026 |
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering ZUG, Switzerland and BOSTON, March 10, 2026 – CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “off |
|
| March 11, 2026 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 12, 2026 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts |
|
| February 12, 2026 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 12, 2026, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU |
|
| February 12, 2026 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON, February 12, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a |
|
| January 12, 2026 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37 |
|
| November 10, 2025 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized T |
|
| October 15, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| October 15, 2025 |
CRISPR Therapeutics AG Up to $600,000,000 Common Shares PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated August 5, 2024) Registration No. |
|
| October 15, 2025 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Newly Registered Securities Fees to Be Paid Equity Common Shares, CHF 0. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 C |
|
| August 4, 2025 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results -CASGEVY®momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with prel |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 4, 2025 |
Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. EXECUTION VERSION COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN SIRIUS THERAPEUTICS AND S |
|
| June 26, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 9, 2025 |
Amended and Restated Articles of Association of CRISPR Therapeutics AG Exhibit 3.1 Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 19, 2025 |
Form of Share Issuance Agreement Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Final Form SHARE ISSUANCE AGREEMENT This SHARE ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of [●], by and among CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incor |
|
| May 19, 2025 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Newly Registered Securities Fees to Be Paid Equity Common Shares, CHF 0. |
|
| May 19, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 19, 2025 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-281262 PROSPECTUS SUPPLEMENT (To prospectus dated August 5, 2024) 1,842,105 Common Shares We are offering an aggregate of 1,842,105 of our common shares, or the Shares, directly to Sirius Therapeutics, or Sirius, pursuant to a Share Issuance Agreement, dated May 19, 2025, or the Share Issuance Agreement, in connection with a C |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 |
|
| May 6, 2025 |
Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety pro |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 16, 2025 |
CRISPR THERAPEUTICS | 2024 ANNUAL REPORT 2024 ANNUAL REPORT Transformative Gene-Based Medicines For Serious Human DiseasesWe are rapidly translating the revolutionary CRISPR technology into therapies to treat a broad range of serious human diseases. |
|
| April 16, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| March 26, 2025 |
CRISPR Therapeutics Announces Transition of Chief Operating Officer Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, March 26, 2025 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportu |
|
| February 11, 2025 |
CRISPR Therapeutics AG Organizational Rules Exhibit 10.35 ORGANIZATIONAL RULES OF CRISPR THERAPEUTICS AG (ORGANISATIONSREGLEMENT) 1. BASIS AND ORGANIZATION 2 2. GENERAL PROVISIONS 2 3. BOARD OF DIRECTORS 4 4. CHAIRPERSON 9 5. CEO 9 6. EXECUTIVE COMMITTEE 10 7. COMPENSATION COMMITTEE 11 8. NOMINATION AND CORPORATE GOVERNANCE COMMITTEE 12 9. AUDIT COMMITTEE 12 10. INDEMNIFICATION 12 11. FINAL PROVISIONS 13 1. BASIS AND ORGANIZATION 1.1 Basis |
|
| February 11, 2025 |
Description of Capital Shares. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 11, 2025, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU |
|
| February 11, 2025 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results -2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activat |
|
| February 11, 2025 |
CRISPR Therapeutics AG Insider Trading Policy. Exhibit 19.1 CRISPR THERAPEUTICS AG INSIDER TRADING POLICY (As amended on September 12, 2024) CRISPR Therapeutics AG (together with its subsidiaries, the “Company” or “we” or “us”) has adopted the following policy and procedures for trading in the Company’s securities (“Insider Trading Policy”). It is designed to prevent the misuse of material nonpublic information, insider trading in securities, |
|
| February 11, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| December 10, 2024 |
CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2430446d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* CRISPR Therapeutics AG (Name of Issuer) Common stock (Title of Class of Securities) H17182108 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 5, 2024 |
Form of Indemnification Agreement Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of by and between CRISPR Therapeutics AG, a Swiss stock corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in order to induce Indemnitee to provide or |
|
| November 5, 2024 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had c |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPE |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| August 5, 2024 |
Form of Senior Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.1 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| August 5, 2024 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respe |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 5, 2024 |
Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Stock Option and Incentive Plan 457(h) 1,000,000 $56. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS |
|
| August 5, 2024 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 CRISPR Therapeutics AG Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Shares, CHF 0. |
|
| August 5, 2024 |
Form of Subordinated Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.2 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| August 5, 2024 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 28th day of May, 2024 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Naimish Patel (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full executi |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 3, 2024 |
Amended and Restated Articles of Association of CRISPR Therapeutics AG Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. |
|
| May 23, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 23rd day of May, 2024 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Julianne Bruno (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full execut |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEU |
|
| May 8, 2024 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results — More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected— —Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indicatio |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 10, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| April 9, 2024 |
2023 ANNUAL REPORT Transformative Gene-Based Medicines For Serious Human DiseasesWe are rapidly translating the revolutionary CRISPR technology into therapies to treat a broad range of serious human diseases. |
|
| April 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU |
|
| February 21, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 16, 2024, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete |
|
| February 21, 2024 |
CRISPR Therapeutics AG Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 CRISPR THERAPEUTICS AG COMPENSATION RECOVERY POLICY Adopted as of October 12, 2023 CRISPR Therapeutics AG (the “Company”) has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company or any of its subsidiaries shall recover Erroneously Awarded Compensation from Covered Persons |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| February 21, 2024 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively – — Clinical trials ongoing for in vivo ge |
|
| February 21, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| February 13, 2024 |
EX-10.1 Exhibit 10.1 INVESTMENT AGREEMENT This INVESTMENT AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2024, by and among CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. |
|
| February 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Newly Registered Securities Fees to Be Paid Equity Common Shares, CHF 0. |
|
| February 13, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258274 Prospectus Supplement (To prospectus dated July 29, 2021) 3,916,082 Common Shares We are offering 3,916,082 common shares, in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement and the accompanying prospectus. The issue price of each common share equals $71.50 Our commo |
|
| February 12, 2024 |
CRSP / CRISPR Therapeutics AG / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 29, 2024 |
CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* CRISPR Therapeutics AG (Name of Issuer) Common stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| January 10, 2024 |
CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| December 13, 2023 |
[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THER |
|
| November 6, 2023 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results -Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD- -Exa-cel assigned PDUFA target action da |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| September 7, 2023 |
Exhibit 99.1 CRISPR Therapeutics Announces Leadership Transition -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and Boston, Mass., September 7, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmac |
|
| August 7, 2023 |
Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, CHF 0. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUT |
|
| August 7, 2023 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SCD and Standard Review for TDT- -PDUFA target action date of December 8, 2023, for SCD and Ma |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023 As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 9, 2023 |
Exhibit 99.2 Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consis |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 9, 2023 |
Exhibit 99.1 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA - - - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) - - PDUFA target action |
|
| June 9, 2023 |
Exhibit 3.1 Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 8, 2023 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and He |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEU |
|
| April 26, 2023 |
2022 ANNUAL REPORT Transformative Gene-Based Medicines For Serious Human DiseasesWe are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat serious human diseasesUNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 11, 2023 |
CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 3, 2023 |
Exhibit 99.1 Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON and ZUG, Switzerland, April 3, 2023 - V |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 29, 2023 |
CRISPR Therapeutics Announces Departure of Board Member Exhibit 99.1 CRISPR Therapeutics Announces Departure of Board Member ZUG, Switzerland and Boston, Mass., March 29, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Director |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 27, 2023 |
Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND CRISPR THERAPEU |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 27, 2023 |
Exhibit 99.1 Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and roy |
|
| March 14, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 14th day of March, 2023 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Raju Prasad (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full executi |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 14, 2023 |
CRISPR Therapeutics Announces Transition of Chief Financial Officer Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and Boston, Mass., March 13, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins C |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| February 21, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts |
|
| February 21, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 21, 2023, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete |
|
| February 21, 2023 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023- -Enrollment |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU |
|
| February 13, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 10, 2023 |
CRSP / Crispr Therapeutics AG / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2023 |
CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| November 1, 2022 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S. submission package expected in Q1 2023; EMA and MHRA submissions are on track for Q4 2022- -En |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THER |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| October 27, 2022 |
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer Exhibit 99.1 CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, Mass. – October 27, 2022 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the Company t |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (C |
|
| September 27, 2022 |
Exhibit 99.1 Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 ? - EMA and MHRA submissions are on track for Q4 2022 ? - Exa-cel granted Fast Track, Regenerative Medicine Adva |
|
| August 8, 2022 |
Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, CHF 0. |
|
| August 8, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 23rd day of May, 2022 between CRISPR Therapeutics, Inc., a Delaware corporation (the ?Company?), and Phuong Khanh Morrow (the ?Executive? and, together with the Company, the ?Parties? or each individually, a ?Party?). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full e |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 8, 2022 |
Exhibit 10.2 Lease Commencement Date Agreement THIS LEASE COMMENCEMENT DATE AGREEMENT, made as of this 1st day of May, 2022, by and between 105 W FIRST STREET OWNER, L.L.C., a Delaware limited liability company (?Landlord?), and CRISPR THERAPEUTICS, INC. (?Tenant?). WITNESSETH: THAT, WHEREAS, Landlord and Tenant have entered into that certain Lease (as amended, the?Lease?) dated as of July 24, 202 |
|
| August 8, 2022 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); discussions with the U.S. Food and Drug Ad |
|
| August 8, 2022 |
SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUT |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| July 13, 2022 |
United States securities and exchange commission logo July 13, 2022 Brendan Smith Chief Financial Officer CRISPR Therapeutics AG Baarerstrasse 14 6300 Zug Switzerland Re: CRISPR Therapeutics AG Form 10-K for the fiscal year ended December 31, 2021 Filed February 15, 2022 File No. |
|
| June 23, 2022 |
June 23, 2022 Ms. Vanessa Robertson Mr. Kevin Vaughn Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: CRISPR Therapeutics AG Form 10-K for the fiscal year ended December 31, 2021 Filed February 15, 2022 File No. 001-37923 Dear Ms. Robertson and Mr. Vaughn: This letter is submitted on behalf of CRISPR Therapeuti |
|
| June 21, 2022 |
CRISPR Therapeutics Innovation Day June 21, 2022 Exhibit 99.1 The presentation and other related materials may contain a number of ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics? expectations about any or all of the following: (i) its plans and expectations for its preclinical s |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 13, 2022 |
Exhibit 99.1 Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to b |
|
| June 13, 2022 |
Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit |
|
| June 13, 2022 |
United States securities and exchange commission logo June 13, 2022 Brendan Smith Chief Financial Officer CRISPR Therapeutics AG Baarerstrasse 14 6300 Zug Switzerland Re: CRISPR Therapeutics AG Form 10-K for the fiscal year ended December 31, 2021 Filed February 15, 2022 File No. |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 13, 2022 |
THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES Swaminathan P. |
|
| June 13, 2022 |
Exhibit 99.2 CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT?-LYM Trial of CTX130? in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress -70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benef |
|
| May 16, 2022 |
Exhibit 99.1 CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief |
|
| May 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 12, 2022 |
Exhibit 99.1 CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130? for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress ZUG, Switzerland and CAMBRIDGE, Mass. ? May 12, 2022 - (GLOBE NEWSWIRE) - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transfo |
|
| May 12, 2022 |
Exhibit 99.2 Abstract Submission 25. Gene therapy, cellular immunotherapy and vaccination - Clinical EHA-1957 THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9?ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES Swaminathan P. Iyer* 1, R. Alejandro Sica2, P. Joy Ho3, Boyu Hu4, Jasmine Zain5, Anca Prica6, Wen-Ka |
|
| May 9, 2022 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - More than 75 patients dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110?, targe |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 9, 2022 |
SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEU |
|
| April 25, 2022 |
DEFA14A 1 crsp-defa14a-2022.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 15, 2022 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110?, targeting CD19+ B-cell malignancies; |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU |
|
| February 15, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware CRISPR Therapeutics Ltd. United Kingdom TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts Casebia Therapeutics Limited Liability Partnership United Kingdom Casebia Therapeutics LLC Delaware |
|
| February 15, 2022 |
Letter Agreement dated December 16, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc. Exhibit 10.32 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. December 16, 2021 Via Overnight Courier Service CRISPR Therapeutics, Inc. 610 Main Street Cambridge, MA 02139 and 200 Sidney Road Cambridge, MA 02142 Re: 610 Main Street, 5th, 6th and 7th Floors, Cambrid |
|
| February 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| February 15, 2022 |
Exhibit 10.37 105 W. First Street Owner, L.L.C. c/o Breakthrough Spaces, L.L.C. Tishman Speyer 45 Rockefeller Plaza New York, New York 10111 January 6, 2022 CRISPR Therapeutics, Inc. 610 Main Street North Cambridge, Massachusetts 02139 Attn: Brendan Smith, Chief Financial Officer RE: Lease (the ?Lease?) dated as of July 24, 2020, between 105 W. First Street Owner, L.L.C. (the ?Landlord?) and CRISP |
|
| February 15, 2022 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 15, 2022, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following description of our common shares is a summary and does not purport to be complete |
|
| February 14, 2022 |
CRSP / Crispr Therapeutics AG / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 9, 2022 |
CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| November 22, 2021 |
Exhibit 99.1 CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110? for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies ZUG, Switzerland and CAMBRIDGE, Mass., November 22, 2021 ? CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today |
|
| November 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| November 3, 2021 |
SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THER |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| November 3, 2021 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022- -Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110? for CD19+ B-cel |
|
| October 14, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 14th day of October, 2021 between CRISPR Therapeutics, Inc., a Delaware corporation (the ?Company?), and Brendan Smith (the ?Executive? and, together with the Company, the ?Parties? or each individually, a ?Party?). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full exe |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| October 14, 2021 |
CRISPR Therapeutics Announces Transition of Chief Financial Officer Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and CAMBRIDGE, Mass. ? October 14, 2021 ? (GLOBE NEWSWIRE) ? CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. S |
|
| October 12, 2021 |
EX-99.1 Exhibit 99.1 CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six |
|
| October 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| October 12, 2021 |
Updated Results from the Phase 1 CARBON Trial of CTX110? October 12, 2021 ? Exhibit 99. |
|
| September 10, 2021 |
CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| July 29, 2021 |
Letter Agreement dated April 29, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc. Exhibit 10.2 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. April 29, 2021 VIA E-MAIL Pfizer Inc. Legal Division 235 East 42nd Street New York, NY 10017 Attention: William C. Longa Re: Sublease dated August 1, 2016 (?5th Floor Sublease?) between Pfizer Inc. (?Pfiz |
|
| July 29, 2021 |
Form of Senior Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.1 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Se |
|
| July 29, 2021 |
As filed with the Securities and Exchange Commission on July 29, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 29, 2021 Registration No. |
|
| July 29, 2021 |
SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUT |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 29, 2021 |
Exhibit 10.1 33 New York Avenue Framingham, MA Second Amendment to Lease CRISPR Therapeutics, Inc. THIS SECOND AMENDMENT TO LEASE (?Second Amendment?) is made as of April , 2021 (the ?Effective Date?) by and between 33 NYA OWNER (DE) LLC, a Delaware limited liability company (?Landlord?), and CRISPR THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Background Pursuant to the provisions of tha |
|
| July 29, 2021 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130? for the treatment of T-cell lymphoma- -Enrollment o |
|
| July 29, 2021 |
Consent of Goodwin Procter LLP (included in Exhibit 5.3) Exhibit 5.3 July 29, 2021 CRISPR Therapeutics AG Baarerstrasse 14 6300 Zug Switzerland Re: Securities Being Registered under Registration Statement on Form S-3 We have acted as U.S. counsel to you in connection with your filing of an automatic shelf registration statement on Form S-3 (as amended or supplemented, the ?Registration Statement?) pursuant to the Securities Act of 1933, as amended (the |
|
| July 29, 2021 |
Form of Subordinated Debt Indenture between the Registrant and one or more trustees to be named EX-4.2 3 d174706dex42.htm EX-4.2 Exhibit 4.2 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Se |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 14, 2021 |
Amended and Restated Articles of Association of CRISPR Therapeutics AG Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit |
|
| June 11, 2021 |
Connecting Hematology For Clinical and Research Excellence VIRTUAL June 9 - 17, 2021 EHA 2021 CTX001? for Transfusion-Dependent ?-Thalassemia: Safety and Efficacy Results from the Ongoing CLIMB THAL-111 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells F. |
|
| June 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 11, 2021 |
Exhibit 99.1 Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001? at European Hematology Association Annual Meeting - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive |
|
| June 11, 2021 |
Connecting Hematology For Clinical and Research Excellence VIRTUAL June 9 - 17, 2021 EHA 2021 CTX001? for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells S. |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 28, 2021 |
DEFA14A 1 crsp-defa14a20210610.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 28, 2021 |
DEF 14A 1 crsp-def14a20210610.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 27, 2021 |
SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEU |
|
| April 27, 2021 |
Exhibit 10.3 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Amendment No. 1 to the Strategic Collaboration and License Agreement This Amendment No. 1 to the Strategic Collaboration and License Agreement (the ?Amendment?) is entered into as of March 17, 2021 (?Amen |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 27, 2021 |
Exhibit 10.1 33 NEW YORK AVENUE FRAMINGHAM, MASSACHUSETTS 01701 LEASE SUMMARY SHEET Execution Date: May 5, 2020 Tenant: CRISPR THERAPEUTICS, INC., a Delaware corporation Tenant?s Mailing Address: 610 Main Street Cambridge, MA 02139 Attention: General Counsel Landlord: CRP/KING 33 NY AVE. OWNER, L.L.C., a Delaware limited liability company Building: 33 New York Avenue, Framingham, Massachusetts 017 |
|
| April 27, 2021 |
Exhibit 10.2 33 New York Avenue Framingham, Massachusetts 01701 (the ?Building?) FIRST AMENDMENT EXECUTION DATE: December 2, 2020 LANDLORD: CRP/KING 33 NY AVE. OWNER, L.L.C., a Delaware limited liability company TENANT: CRISPR THERAPEUTICS, INC., a Delaware corporation PREMISES: Areas on the first (1st) floor of the Building, the Generator Area, the Loading Dock Premises, and the roof of the Build |
|
| April 27, 2021 |
Exhibit 10.4 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. AMENDED AND RESTATED Joint Development and Commercialization AGREEMENT BETWEEN vertex pharmaceuticals incorporated VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CriSpr THERAPEUTICS AG CRISPR THERAPEUTICS LI |
|
| April 27, 2021 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - Granted Priority Medicines designation by the European Medicines Agency for CTX001? for transfusion-dependent beta thalassemia (TDT)- -More than 30 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 20 |
|
| April 20, 2021 |
Exhibit 99.1 Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001? in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CR |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 5, 2021 |
PRE 14A 1 crsp-pre14a20210610.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| February 16, 2021 |
EX-4.1 3 crsp-ex4117.htm EX-4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 16, 2021, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and |
|
| February 16, 2021 |
Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 - - The first patient treated in the CLIMB-Thal-111 trial completed two years of follow-up and has enrolled in the l |
|
| February 16, 2021 |
Amended and Restated Articles of Association of CRISPR Therapeutics AG, dated January 27, 2021. EX-3.1 2 crsp-ex319.htm EX-3.1 Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpo |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
